lung cancer

News

Jazz targets US launch of SCLC drug after FDA grants fast re...

PharmaMar and Jazz Pharmaceuticals have announced the FDA has granted a six-month Priority Review for their lurbinectedin for relapsed small cell lung cancer (SCLC).

News

FDA to quickly review Novartis' capmatinib in rare lung canc...

The FDA has agreed to fast-track its regulatory review of Novartis’ capmatinib in a hard-to-treat form of lung cancer.

News

Boosted by Celgene's cash, BMS bounces back after mega-merge...

Bristol-Myers Squibb’s $74 billion mega-merger with Celgene seems to have been vindicated after a set of glowing full-year results from the previously struggling pharma.

News

BMS plans another tack as EU regulators knock back lung canc...

Bristol-Myers Squibb has withdrawn a European filing of its immunotherapy combination of Opdivo and Yervoy in first line lung cancer after a knock back from regulators, and plans a differen

News

NHS patients denied new lung cancer drug after another NICE ...

Certain untreated lung cancer patients on England's NHS will have to make do with older drugs after NICE ruled in final guidance that AstraZeneca’s Tagrisso (osimertinib) is not cost-effect

Views & Analysis